The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

SIMPLE SUMMARY: Although taxane-trastuzumab-pertuzumab combinations in the first-line treatment setting significantly improved clinical outcomes in patients with Human Epidermal growth factor Receptor 2 positive (HER2+) advanced breast cancer (aBC), their clinical efficacy is highly heterogeneous, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligorio, Francesca, Fucà, Giovanni, Zattarin, Emma, Lobefaro, Riccardo, Zambelli, Luca, Leporati, Rita, Rea, Carmen, Mariani, Gabriella, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073809/
https://www.ncbi.nlm.nih.gov/pubmed/33921727
http://dx.doi.org/10.3390/cancers13081964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073809/
https://www.ncbi.nlm.nih.gov/pubmed/33921727
http://dx.doi.org/10.3390/cancers13081964

Ejemplares similares